Longeveron (LGVN) Reports Q4 Loss of $0.20/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/26/2026
- Wall Street dips on hot inflation data ahead of Nvidia earnings
- Oil rises as investors weigh Hormuz talks
- Meta to pay up to $16.68 billion in mass social media settlement
- Anthropic agrees to $45bn cloud computing deal with Nscale - report
- Citi sees an opportunity in Oracle after ’one of the most extreme’ stock drawdowns
- Boston Scientific discloses cybersecurity incident causing global disruption
- Wall Street ends higher as tech rebounds before Nvidia results
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- FDA approves Revolution Medicines pancreatic cancer drug Rasonque
Longeveron Announces Fourth Quarter and Full Year 2021 Financial Results and Operational Progress
March 11, 2022 8:00 AM ESTCurrently Enrolling Clinical Trials with Lomecel-B in Three Disease Indications: Hypoplastic Left Heart Syndrome (Phase 2a), Alzheimers Disease (Phase 2a), and Covid-related Acute Respiratory Distress Syndrome (Phase 1)
Lomecel-B for HLHS Granted Rare Pediatric Disease and Orphan Drug Designation by the US FDA
Japanese Phase 2 Aging Frailty Trial Expected to Initiate in First Half of 2022
Multiple Clinical Data Publications Expected in 2022
- Conference Call Today at 8:30 a.m. EST -
MIAMI, March 11, 2022 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:... More
